LAWRENCE, Mass., Nov. 18, 2014 /PRNewswire/
-- NxStage® Medical Inc. (Nasdaq: NXTM), a leading
manufacturer of innovative dialysis products, today announced the
launch of its new Streamline® Express dialyzer for the
in-center, hemodialysis market. Streamline Express features a
pre-attached blood tubing set, which is designed to reduce the
amount of labor required for machine set-ups and to reduce the
number of touch point contamination sites. The dialyzer
enables achievement of high clearances due to even dialysate
distribution and low protein adsorption which limits performance
drop in the course of treatment.
Streamline Express combines the NxStage dialyzer, which has been
used in nearly 10 million treatments, with Medisystems'
market-leading bloodline, Streamline, which is used in over 20
million dialysis procedures annually. Streamline Express is
designed to eliminate blood-air interfaces, which may reduce the
risk of clotting.
"We continue to innovate and add value for our Medisystems
in-center customers," said Joe Turk,
President of NxStage Medical, Inc. "We are very excited about the
potential for Streamline Express to deliver improved efficiency for
providers and, most importantly, high clearances for patients."
The Streamline Express single use, gamma sterilized dialyzer is
manufactured from glycerin-free polyethersulfone membranes
(Purema® H). The Streamline Express is available for the
Fresenius® 2008® and B. Braun hemodialysis
machines.
Medisystems is a wholly-owned subsidiary of NxStage Medical,
Inc.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device
company, headquartered in Lawrence,
Massachusetts, USA, that develops, manufactures and markets
innovative products for the treatment of ESRD and acute kidney
failure. For more information on NxStage and its products, please
visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including the Quarterly Report on Form 10-Q for the quarter ended
June 30, 2014. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Contact:
Kristen K. Sheppard, Esq.
VP,
Investor Relations
ksheppard@nxstage.com
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
SOURCE NxStage Medical Inc.